Seeking Alpha

JPMorgan says there's a strong likelihood the FDA is going to approve Amarin's (AMRN) high...

JPMorgan says there's a strong likelihood the FDA is going to approve Amarin's (AMRN) high triglyceride drug AMR101 when it meets on Thursday. Based on the approval, the firm sees a fair price for the shares of around $22 by the end the year. Expect some volatility on the way however, the last time the stock hit those levels was clear back in 2007.
Comments (2)
  • Moosh
    , contributor
    Comments (125) | Send Message
     
    I am long AMRN regardless what JPM says. All the share holders will be rewarded more then $22 my guess is $24-$26. Like to hear other thoughts please.
    23 Jul 2012, 08:40 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    The $22 PT does NOT include takeout or major partnership.
    24 Jul 2012, 08:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|